Coloplast Appoints Gavin Wood, Former Johnson & Johnson Executive, as New CEO

According to biospace report,Coloplast Board recently announced the appointment of Gavin WoodAs the new President and CEO of the Group, the appointment will take effect officially from May 1, 2026.He will succeedLars RasmussenThe position of interim CEO,Lars RasmussenEffective May 5, 2025, assuming the position.

GAvin Wood forCanadian nationality, currently residing in Switzerland, will relocate to Denmark for work after taking office. HeHolding a Bachelor of Laws degree from Carleton University in Canada and a Master of Business Administration degree from Queen's University in Canada.

G has held various management positions at Johnson & Johnson for two decades.Avin Wood recently served as the Group Chairman of Johnson & Johnson Medical Technologies for the Europe, Middle East, and Africa region, overseeing this multi-billion-dollar business sector, leading more than 7,000 employees, with operations spanning three major divisions: Surgery, Orthopaedics, Cardiovascular, and Specialty Solutions.

In the early stage of his career, he worked at Johnson & Johnson's Ethicon.Global President of the (Ethicon) Wound Closure and Healing Division. In addition, he also serves as the Vice Chairman of the European Medical Technology Industry Association.

The interim chairman of the board of Coloplast said: "GAvin is a senior executive in the medical technology industry, with remarkable achievements in creating value and driving business growth. He possesses exceptional business operational capabilities and valuable experience from working at multiple medical technology companies. Having led global commercial operations, he has an in-depth understanding of both European and American healthcare markets. The board firmly believes that he is the right person to lead the company into a new chapter of growth and value creation, and he will work with the executive team to advance the implementation of the 'Impact 4.0' strategy."

GAvin Wood said, "I am deeply honored and excited to join Coloplast. This company has a strong development foundation, a rich portfolio of innovative products, and a clear mission to help people improve their quality of life. In the future, I will drive the continuous growth of the company's business, increase investment in talent cultivation, implement the 'Impact 4.0' strategy, and create value and bring tangible impact to all our stakeholders, customers, product users, and patients."

At the same time,Lars Rasmussen Will continue to serve as the interim CEO, overseeing Coloplast's operations until the end of April.

In May 2025, Kristian Villumsen, then President and CEO of Coloplast, resigned. Lars Rasmussen, Chairman of the Board, took over as interim CEO. The appointment of Gavin Wood has ended nearly a year of interim management at the company. Coloplast is a well-known Danish medical device company and a leading player in the global wound care market. In the 2024/25 fiscal year (October 2024 - September 2025), its revenue reached 27.9 billion Danish kroner, with an organic growth of 7% year-on-year.

Compiled from: biospace